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Abstract
Background:  Drug promotion has an important bearing on the rational use of drugs.
Aim: To determine the impact of pharmaceutical promotion on the decision-making process of
prescription of doctors working in Addis Ababa.
Methods:  Cross-sectional study was conducted with the participation of randomly selected 313
doctors practicing in Addis Ababa. A self administered structured questionnaire was used. The
questionnaire included questions regarding socio-demographics, factors affecting prescribing
decision, self-reported and self-rated effect of the activities of Pharmaceutical Sales
Representatives (PSRs) on doctors prescribing decisions.
Results: Overall response rate was 300/313 doctors (96%). Of the total respondents, 81.3%
reported that their prescribing decisions were affected by promotional activities. Socio-
demographic characteristics of doctors’ were not found to be related factors that affect their
prescribing behaviours by drug promotion activities. The extent of exposure to promotional
activities was found to be higher among doctors who reported affected by drug promotion
(P=0.01). Doctors who perceived that gifts from PSRs are appropriate or PSRs as valuable
source of drug information were reported their prescribing behavior highly affected.
Conclusions and Recommendations: As a group, doctors are at risk for influence by
promotional activities. The extents of exposure to drug promotion activities and doctors’
perception about gifts from PSRs were found to be important factors that affect prescribing
behavior.. Government bodies and/or professional societies should provide drug information
services and implement effective control mechanism to limit the influence posed by drug
promotion activities. Further research may be required to understand exactly how much
influence and to what degree promotional activities affect physicians’ prescribing behaviors.
11. Introduction
Promotional activities are communication activities through which a company passes across the
benefits of its product and services to its target customers. No matter how successfully developed
a product may be, it is worthless except its benefits are made clear and appreciated by the target
customers. The World Health Organization defines drug promotion activities as "all
informational and persuasive activities by manufacturers and distributors, the effect of which is
to induce the prescription, supply, purchase and/or use of medicinal drugs." 1 Drug promotion
has an important bearing on the rational use of drugs; on drug price-control mechanisms,
availability and use of essential drugs, on equity of drug distribution and the cost of health care.
It thus becomes a public health issue of concern. 2, 3
According to a fact sheet by WHO (May, 2010) about the rational use of medicines, more than
50% of all medicines are not correctly prescribed. The situation is worse in developing countries,
with less than 40% of patients in the public sector and less than 30% in the private sector being
treated according to clinical guidelines. Promotional activities of medical representatives and
other promotional activities by pharmaceutical companies, is identified as the major factor
contribute to the incorrect use of medicines. 4 In relation to this, the World Health Organization’s
Department of Essential Drugs and Medicines Policy maintains a database of such promotional
activities at http://www.drugpromo.info/.
Pharmaceutical companies invest large sums of money promoting their products. In 2002, almost
US$21 billion was spent on promotion in the USA. These amounts are at least 30 times what
national governments spend on drug information (for example, in Italy: US$4475/doctor by the
pharmaceutical industry versus US$180/doctor by the government). In Canada in 2000 there
were over 3.4 million visits by sales representatives to doctors, leaving behind 21.5 million drug
2samples and in the USA companies organized over 300, 000 events for doctors.5 Sales
representatives are frequently the only source of information about medicines in developing
countries where there may be as many as one representative for every five doctors.6 Although
these practices are commonly used, little has been published about the attitude of doctors
concerning their interaction with the pharmaceutical industry. Recent research suggests that
interactions between doctors and pharmaceutical companies affect doctor requests to add
medications to hospital formularies as well as prescribing behavior. 7, 8 Other observational
studies showed that exposure to promotion and doctors positive attitudes towards promotion both
correlate with irrational use of pharmaceuticals.10-25
In Ethiopia, pharmaceutical companies, especially those that deal with prescription drugs operate
in a very competitive environment because of the existence of various brands of generic drugs.
The competitive nature of the business environment makes it mandatory for them to develop and
implement strong promotional strategies in order to gain and maintain a reasonable share of the
market.
More than 90 pharmaceutical sales representatives representing around 15 manufacturers are
practicing in Ethiopia. However, the impact of drug representatives and other promotional
activities on doctors’ prescription decision and hence in rational drug use is not yet studied.
Studies in this area are crucial in developing ethical criteria for drug promotion and enforce
regulations to make the ethical criteria effective by Food, Medicine and Health Care
Administration and Control Authority of Ethiopia of Ethiopia (FMHACA) which is mandated
to control drug promotional activities. This study is therefore to determine the impact of drug
promotional activities of pharmaceutical companies on the decision-making process of drug
prescription ordered by doctors working in Addis Ababa.
32. Literature Review
Several studies assessed the impact of the doctors- pharmaceutical industry interaction on the
knowledge, attitudes, and prescribing practices of doctors. The drug industry manufactures,
distributes, and publicizes powerful chemical and biologic agents that have proven benefits and
that doctor sometimes fail to use as often as they should, or in sufficient doses.9 In this sense,
industry’s efforts to encourage the use of some agents by doctors can be seen as contributing to
the public health. At the same time, the marketing by the drug industry of its products to doctors
is manifestly aimed also at improving industry profits; in the process, such marketing may
contribute to less savory social consequences, including increasing drug costs and the misuse or
overuse of medications in ways that may adversely affect patients.10
Drug promotion to doctors takes five main forms: detailing by pharmaceutical sales
representative, printed promotional materials, gifting, drug samples, and sponsoring continuing
medical education (CME). 11
Doctors in practice often rely on pharmaceutical sales representatives to provide them with
information about existing and new pharmaceutical products. 12,13 These representatives are not
clinicians, but have been trained, sometimes inadequately, to provide information about new
drugs and to promote pharmaceutical products. Although pharmaceutical sales representatives
serve an educational function, they are employed by large for-profit corporations. Visits by
pharmaceutical sales representatives may lead to increased utilization of specific pharmaceutical
products, and doctors are influenced by commercial information disseminated at such visits,
sometimes unknowingly.14
Studies from several countries show that roughly 80-95% of physicians interact with
pharmaceutical representatives even though the evidence shows the information they provide is
4skewed (even slightly) in favor of the drug being promoted, resulting in inappropriate prescribing
habits.15,16 Industry interactions correlate with doctors’ preferences for new products that hold no
demonstrated advantage over existing ones, a decrease in the prescribing of generics, and a rise
in both prescription expenditures and irrational and incautious prescribing.17,18
Reviews of information presented by pharmaceutical sales representatives have noted that
pharmacologic information is often inaccurate. In Britain, Canada, New Zealand, and the United
States 80-90% of doctors see pharmaceutical representatives. Of statements made by
pharmaceutical representatives 11% are false and of the false statements all are in favor of the
representatives' drugs. While very few doctors consider themselves susceptible to detailing, 84%
of them believed that their colleagues are.19
Studies found that there is an association between meetings with pharmaceutical representatives
and formulary addition requests for the drug of the representative’s company, both with respect
to control doctors who did not meet representatives and with respect to requests for other
companies’ drugs. Most of the requested drugs presented little or no therapeutic advantage over
existing formulary drugs.7, 8 Interactions with pharmaceutical representatives were also found to
impact the prescribing practice of residents and doctors in terms of prescribing cost, non-rational
prescribing, awareness, preference and rapid prescribing of new drugs, and decreased prescribing
of generic drugs. 2, 20,21,22,23, 24
Gifts from the Pharmaceutical Sales Representatives can be as innocuous as pens, note pads,
medication samples, and fast food, or as substantial as travel, cash honoraria, and research
support. Irrespective of the content, gifting is ubiquitous. A survey noted that 92% of doctors had
received free drug samples, 61% had received meals, free access to entertainment, sporting
events or travel, and nearly one in seven had received financial benefits. 25, 26 Social science
5research continues to show that the impulse to reciprocate from even a token gift can be a
powerful influence on behavior, thereby producing a possible conflict of interest for the recipient
(doctor). This conflict of interest exists when there is an inconsistency between an ethical or
professional interest and self-financial concern. This becomes evident when pharmaceutical
companies persuade doctors to write prescriptions, an act not only with financial and health
sequelae for the patient, but with possible financial consequences for the doctor. A classic study
has shown that most doctors (61%) believe that they are not influenced by detailers’ gifts;
however, they believe the same is true for only 16% of their colleagues. Medical students
acknowledge gifts as more difficult ethically for professions other than their own. 27,28 Such
findings echo social science research, demonstrating that, although bias is identifiable, it tends to
be preferentially attributed to others. 29
It is difficult to believe that a doctor is impervious to industry incentives and that accepting gifts
does not influence their behavior on some level. Physicians tended to believe that it was
appropriate to receive inexpensive gifts. There is no such thing as a “free” lunch: accepting gifts
from pharmaceutical companies allows for a potential conflict of interest between the doctor and
patient, which in some cases may be unethical. A study showed association between benefiting
from sponsored meals and formulary addition requests for any drug and it was clearly dose-
related.30
Another role that pharmaceutical promotion often plays is providing drug samples to doctors. Of
the total money spent on drug promotion in the US in 2004, roughly 30% has been attributed to
samples. This is only second to detailing, which comprises 36% of all promotional spending.
Pharmaceutical companies expect to get a return on this investment. Studies showed that
6samples do influence prescribing behavior. When samples run out, a prescription is usually
written for the sampled drug. 31, 32
Studies showed that often samples never reach their intended audience. Many samples are
appropriated by doctors for personal or family use or end up in an ‘‘unknown destination’’.33,34
And in one study, nearly half of pharmaceutical representatives surveyed reported using samples
themselves or giving them to their friends and relatives.35 These studies indicate that samples
often reach the wrong people and are frequently misused. It is difficult to escape the conclusion
that the prime motivation behind the provision of free samples is marketing. Samples have a
major influence on doctors’ prescribing habits. 36,37,38 Samples are one of the most effective ways
sales representatives get their foot in the door to pitch their companies’ products. The technique
is effective; the availability of samples is associated with rapid prescription of the new drug.39 In
one study, residents with access to samples were more likely than their counterparts without
samples to prescribe heavily advertised products and less likely to suggest an over-the-counter
alternative.40 And a survey based on self-reported doctor judgments suggests that the availability
of samples might even influence doctors to prescribe drugs that would not otherwise be their top
choice.41
Samples are not effective in lowering patients’ costs. Indeed, evidence shows that patients who
received free samples had higher out-of-pocket costs than their counterparts who were not given
free samples. Samples raise the cost of health care, as companies recoup marketing costs through
higher prices and increased sales volume. Samples constitute an enormous promotional outlay of
pharmaceutical companies.42
7In a study it was found that accepting funding to attend a symposium was independently
associated with increased formulary addition requests for the sponsor’s drug. This interaction
was also found to impact hospital prescribing practices two years after groups of doctors
accepted all-expenses-paid trips to a drug-sponsored symposium.2, 43
Two studies revealed that resident exposure to pharmaceutical representative speakers at lunch
rounds was associated with dissemination and learning of inaccurate information about the
sponsor’s and competitor’s drug. In these studies, attendance at rounds given by a doctor
pharmaceutical representative was associated with appropriate and inappropriate treatment
decisions by attending residents, independent of variables including the resident’s memory of the
presenter’s affiliation. 44, 45
One marketing approach used by many pharmaceutical companies is to provide financial support
of continuing medical education (CME) programs. 46,47 Doctors attend CME programs for many
reasons, including fulfilling state medical licensure requirements, maintaining hospital privileges
and specialty society memberships, and obtaining new knowledge and skills. Many doctors also
regard CME courses as their most valuable source for clinical information. 48 However, evidence
suggests that CME programs sponsored by industry not only may be more biased (in favor of the
sponsoring companies’ products) than programs not sponsored by industry but also may
influence doctors’ professional behavior (eg, increased prescriptions of the sponsor’s
medication). These findings raise the ethical concern of industry influence on doctors who
participate in CME programs.2, 37, 49
Studies also showed the influence of various factors on prescribing amounts. The doctor’s age,
training, environment and health-care demand have been quoted as explanatory factors for
prescription amount variables.50, 51
8Although some positive outcomes were identified (improved ability to identify the treatment for
complicated illnesses), most studies found negative outcomes associated with the interaction.
These included an impact on knowledge (inability to identify wrong claims about medication),
attitude (positive attitude toward pharmaceutical representatives; awareness, preference, and
rapid prescription of a new drug), and behavior (making formulary requests for medications that
rarely held important advantages over existing ones; non-rational prescribing behavior;
increasing prescription rate; prescribing fewer generic but more expensive, newer medications at
no demonstrated advantage.)
Here a question arises, “Are the pharmaceutical promotional activities really able to influence the
behaviors of the doctors in our context?” This study is therefore, aimed at to determine the self-
reported impact of drug promotional activities of pharmaceutical companies on the decision-
making process of drug prescription ordered by doctors working in Addis Ababa.
93. Objective
General Objective
 To determine the effect of pharmaceutical promotion on the decision-making process of
prescription of doctors in Addis Ababa.
Specific Objectives
 To determine the proportion of doctors influenced by promotional activities of drug
companies
 To compare differences in factors affecting prescribing according to self-reported prescribing
behaviours.
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4. Methods
4.1. Study area
The study was conducted in Addis Ababa, the capital city of Ethiopia and the social, political,
and economic center of the country. It is located in the geographic center of the country and
covers a landmass of 540 sq. km. Addis Ababa has an estimated population of 2.98 million
(Central Statistical Agency 2008) and is divided into 10 sub-cities.52 There are 11 government
hospitals, 30 private hospitals and 169 higher clinics in Addis Ababa.53 More than 90
pharmaceutical sales representatives who were representing around 15 manufacturers were
practicing in Ethiopia.
4.2. Study Design
Cross-sectional study was conducted with the participation of doctors of different specialty who
are practicing in Addis Ababa public and private health facilities (Hospitals and Higher Clinics).
4.3. Source Population
The source of population was all doctors working in hospitals and higher clinics in Addis Ababa.
Out of 934 practicing doctors in Addis Ababa 396(42.3%) were general practitioners and
538(57.7%) were specialists. The proportion of doctors by sex was 82.4% and 17.6% for male
and female, respectively .53
4.4. Study Population
The study population was those selected doctors working in hospitals and higher clinics in Addis
Ababa.
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4.5. Inclusion Criteria
Doctors who were practicing in clinic(s) and actively prescribing drugs for their patients,
working in hospitals and higher clinics in Addis Ababa were included in the study.
4.6. Exclusion Criteria
Excluded from the sample were physicians who are not authorized to prescribe, either because
they belonged to a specialty that is not common to prescribe (radiology, nuclear medicine,
microbiology, and anaesthesiology) or in administrative positions.
4.7. Sample Size Calculation
This study was planned to determine what proportion of doctors were affected by drug
promotion on their decision-making process of writing prescription. The level of precision was
supposed to be a 95% confidence limit and no wider than 5% (i.e. 0.05). Studies have shown that
roughly 90% of physicians interact with drug companies resulting in inappropriate prescribing
habits18.
Therefore, the sample size will be no = Z  2 P (1-P) = (1.96)2 .9(.1)
2          d2 (0.05) 2 = 139
Finite population correction factor,
n = no = 139 = 121
(1 + no/N) 1+139/934
In addition, as the proportion of doctors influenced in their prescribing decision is varied in
different studies for different promotional activities, sample size was calculated in relation to
four important promotional activities as follows:
 Around 934 doctors are expected to be practicing in Addis Ababa private and public hospitals and higher clinics
12
Factors Proportion (P) of doctors
influenced by the factor in
their prescribing decision
Formula Sample
Size
Interaction with PSRs 49% 20, 21 no = Z  2 P (1-P)
2          d2
Finite population
correction factor,
n = no
(1 + no/N)
272
Gifts (including
sponsored meals)
27% 20, 21 228
Medical samples 79% 21, 35 200
Sponsored CME
trips/conferences
42% 21, 35, 40 267
Therefore, with a 15% contingency (272*0.15 + 272) 313 doctors were selected randomly from
the target population.
4.8. Sampling procedure
Figure 1 shows selection procedure of doctors practicing in hospitals and higher clinics in Addis
Ababa. First, simple random sampling technique was employed to select 9 government hospitals,
15 private hospitals and 28 higher clinics. Sample selection was preformed based on 5 to 1 of
male to female ratio and nearly 4 to 3 ratios of specialist and general practitioners. Thus, 17
doctors from each government hospital and 7 doctors from each private hospital were selected
randomly. The numbers of doctors practicing in each higher clinic was few in number, ranges
from 2 to 5, and therefore 2 samples were taken from each randomly selected facility.
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Figure 1: Selection procedure of doctors practicing in hospitals and higher clinics in Addis
Ababa.
4.9. Data Collection Technique
Study subjects were informed on the study objective and data was collected via a self-
administered structured questionnaire by the researcher. The questionnaires were filled out by
the doctors in the presence of the researcher. When the doctors were not able to fill out the
questionnaires because of the heavy workload or were not available, they were visited a second
and third time. Doctors were provided with a letter explaining the purpose of the study and
verbal consent were obtained to participate in the study.
Doctors practicing in
Hospitals and Higher
Clinics in Addis
N=313
Doctors practicing in
11 Government
Hospitals
Doctors practicing in
30 Private Hospitals
Doctors practicing in
169 Higher Clinics
Doctors practicing in
selected 9 gov.t
hospitals
Doctors practicing in
selected 15 Private
Hospitals
Doctors practicing in
selected 28 Higher
Clinics
17 samples in each
Hospital
7 samples in each
hospital
2 samples in each
Higher Clinic
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4.9.1. Questionnaire
The questionnaire was designed to be close-ended questions. The questionnaire was pre-tested
for content and design on 10-20 doctors who were working in private and public hospital out of
Addis Ababa. Modification was done so that the questionnaire is simple to answer and give
meaningful data. The questionnaire was composed of the following four main parts: part (A) to
provide information with regard to the demographic and other characteristics of the respondents;
part (B) to describe about prescribing decision and its determinants; part (C) to describe about
doctors exposure to promotional activities; and part D to describe the impact of drug promotion
activities on prescribing behaviours.
There were 16 questions to measure the self-reported and self-rated effect of pharmaceutical
promotion on prescribing in the questionnaire (See questions in Annex-II). Regarding question 1,
the answers of 1–2, 3–4 and 5–6 were classified as low, moderate and high, respectively. For
Question 2, the answers of 1–2, 3–4 and 5–6 were also classified as rarely, sometimes and
frequently, respectively. For question 9, the answers of "yes/always" and "yes/sometimes" were
combined and compared to the answer "Never".
In addition to sex, years in practice, specialty and practice setting, respondents were also asked
how much opportunity they had had to learn physician-pharmaceutical industry relationships and
critical appraisal skills on a five-point scale (none, little, a little, some, substantial).
Respondents were also asked to report the frequency of meetings with PSRs and receiving or
participating in various types of gifts or promotional events on a five-point scale: never = 0, once
or less than once a month= 1, two to three times a month = 2.5, once a week= 4, two to three
times a week =10, nearly every day= 20 (Annex II). Responses to these questions were summed
to create a ‘‘Exposure Index’’ (range 0–120). The Index expressed the frequency of meeting with
15
PSRs and receiving gifts or participating in the promotional events listed in a typical four-week
period.
Respondents were also asked to report their degree of agreement with a series of ten statements
about relationships with PSRs on a five-point scale: agree, somewhat agree, neutral, somewhat
disagree, and disagree (see annex-II). Principal component factor analysis for these ten
statements extracted three factors. They consisted of five items (Q. 13a, 13b, 13c, 13d, 13e) for
which disagreement suggests that they are immune from influence by interactions with
pharmaceutical promotion, two items (Q. 13g, 13h) for which agreement suggests that they
believe receiving gifts is appropriate and two items (Q. 13i, 13j) for which agreement suggests
that respondents believe that PSRs are a valuable source of information. The points for each of
these three factors were converted to a summary score ranging from 0 to 1.0. A score of 0 was
assigned to physician perception of promotional activities as having minimal informational
value, themselves as minimally immune to promotion, and gifts as totally inappropriate. A score
of 1.0 was assigned to physician perception of promotional activities as having maximal
informational value, themselves as maximally immune to promotion, and gifts as totally
appropriate.
4.9.2. Data Quality Assurance
The questionnaire was pretested for its validity and reliability before being administered in the
study. All the data was checked for completeness, accuracy, clarity and consistency by the
principal investigator and the supervisor immediately after data collection. The principal
investigator and supervisors closely monitored the data collection process.
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4.10. Data Analysis Technique
To assess drug promotion activities as a reason for change in prescribing practice proportion of
doctors, who reported that their prescribing decisions were affected, was computed.
Characteristics of doctors as determinants of the self-reported effect were analyzed with the
logistic regression analysis. Pearson product-moment correlations were used to characterize
relationships between Exposure Index and each of three Attitudinal Scores. T-tests were used to
compare Exposure Index of two groups of doctors with different self-reported prescribing
behaviors; differences in the extent of exposure to each type of promotional activities among
affected and never affected doctors according to self-reported prescribing behaviour. To compare
differences in the extent of exposure to or attitudes toward promotional activities according to
self-reported prescribing behaviours T-test were also used. P value under 0.05 was considered to
be significant. All p values were 2-tailed. SPSS, version 15.0 was used for all statistical analyses.
4.11. Ethical Consideration
The study proposal was duly reviewed and approved by Gondar University IRB, subsequently
reviewed and approved by Addis Ababa Health Bureau IRB. The purpose of the study was
explained to institutions where the study was conducted and to the study subjects. Verbal
informed consent was obtained from all study participants before administering the questionnaire
by the researchers. The study was conducted if participant confirms his/her willingness to take
part in the interview. It is participants’ right to escape questions; stop the interview at any time.
Privacy and data confidentiality were ensured by putting codes instead of participants name in
the filled questionnaire and placing it in locked cabinet so that others except the researcher can
hardly access the data.
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4.12. Variables Definition
 Influenced/affected Doctor: A doctor is influenced or affected by pharmaceutical
promotion activities when he/she tends to modify his/her prescribing behavior as a
result of activities related to pharmaceutical promotion.
 Exposure Index: The range of the index was from 0 to 120. The Index expressed the
frequency of meeting with PSRs and receiving gifts or participating in the
promotional events listed in a typical four-week period.
 Immunity Score: The range of the score was from 0 to 1.0. The score of 0 was
interpreted as the doctors’ perception about themselves as minimally immune against
promotion and 1.0 maximally immune.
 Informational Value Score: The range of the score was from 0 to 1.0. The score of 0
was interpreted as the doctors’ perception about PSRs being minimal informational
value and 1 maximal information value.
 Appropriateness Score: The range of the score was from 0 to 1.0. The score of 0
was interpreted as the doctors’ perception about gifts being as totally inappropriate
and 1.0 being totally appropriate.
4.13. Operational Definitions
a. Drug (or Pharmaceutical): Drug means any substance or mixture of substances or
medical equipment or supplies, used for human and animal health care (i.e diagnosis,
treatment, mitigation or prevention of diseases or symptoms) including poisons, narcotics
and psychotropic substances, chemicals, blood and blood products, vaccines, sera,
18
radioactive pharmaceuticals, medicated cosmetics and sanitary products, household and
industrial pesticides, medicated food stuffs, and Animal feed additives.54
b. Drug/Pharmaceutical Promotion:
 Drug promotion is defined as "all informational and persuasive activities by
manufacturers and distributors, the effect of which is to induce the prescription,
supply, purchase and/or use of medicinal drugs."55
 Drug Promotion activities involve five main forms: detailing by pharmaceutical sales
representative, printed promotional materials, gifting, drug samples, and sponsoring
continuing medical education (CME).56
c. Pharmaceutical Sales Representative (PSR): means a representative of a
manufacturing firm directly or through the distributor, licensed by the Authority to
conduct promotional activities through provision of information on the drugs
manufactured by the firm.57
d. Visit (or Detailing). The term “visit,” as it applies to Pharmaceutical Sales
Representatives, refers to any contact with medical staff, to induce the prescription,
supply, purchase and/or use of drugs.58
e. Printed Drug Promotional Material: the term promotional materials include
promotional labeling and advertisements. Examples of labeling include, but are not
limited to, brochures, booklets, detailing pieces, bulletins, calendars, motion pictures, and
slides. Advertisements include, but are not limited to, materials published in journals,
magazines, other periodicals, and newspapers.59
19
f. Gifts: Gifts from the Pharmaceutical Sales Representatives can be as innocuous as pens,
note pads, medication samples, and meals or as substantial as travel, cash honoraria, and
research support.60
g. Drug Samples: Prescription and non-prescription medications which are provided to the
sites by pharmaceutical representatives for complimentary distribution to patients, as
starter doses.61
20
5. Result
Study Population
Overall response rate was 300/313 doctors (96%). Table 1 displays the doctors’ characteristics.
Of the subjects, 81.7 % were male and 35.7% were general practitioners, 42.6% were specialists
and 21.7% were residents. Among doctors reporting year of practice, 55.1% were less than 10
years of practice. Of the respondents 55.4%, 26% and 17.8% were working in public hospital,
private hospitals and higher clinics in regular basis, respectively. As the place of study, 39.2%
were graduates of AAU, 16% were graduates of universities outside Ethiopia and the rest 44.8%
were graduates of Gondar University, Jimma University and Mekelle University.
Thirty seven percent of respondents reported having had opportunities to learn physician-
industry relationships and 65.7% reported have learned critical appraisal skills. Of the doctors,
81.3% reported that their prescribing decisions were affected by drug promotion activities; and
they believe the same is true for 91.2% of their colleagues.
Factors, which are rated by doctors that affect their prescribing decisions and the frequency of
using reference sources in case of any problems in their prescribing process, have been shown in
Table 2. The most frequent resources used in case of any problems in prescribing process were
medical books (73.1%) and academic journals (39%). Drug guides of pharmaceutical companies
(40.2%) and the documents of pharmaceutical companies other than drug guides (43.2%) were
the least frequently used resources. The doctors endorsed that self reading after graduation
(66.4%), pharmacology courses at medical school (56.1%) and post-graduate in-service training
(54.9%) had high effect on their prescribing decisions. Activities of pharmaceutical promotion
(46.8%) and consultation with other physicians (47.8) had moderate effect according to the
doctors’ statements.
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Table 1: Characteristics of 300 respondents
Characteristics Respondents
No./Total No Percentage
Sex
Male
Female
245/300
55/300
81.7
18.3
Years of practice
1-3
4-6
7-9
10 and above
76/296
55/296
32/296
133/296
25.7
18.6
10.8
44.9
Work Setting
Public Hospital
Private Hospital
Higher Clinic
165/298
80/298
53/298
55.4
26.8
17.8
Specialty
Internal Medicine
Surgery
Orthopedics
Pediatrics
Obstetrics/gynecology
Dermatology
Psychiatry
Ophthalmology
General Practitioner
Resident
47/300
6/300
5/300
31/300
21/300
5/300
4/300
9/300
107/300
65/300
15.7
2.0
1.7
10.3
7.0
1.7
1.3
3.0
35.7
21.7
University
Addis Ababa University Graduates
Gondar University Graduates
Jimma University Graduates
Mekele University Graduates
Others (Universities out side Ethiopia Graduates)
113/288
75/288
53/288
1/288
46/288
39.2
26.0
18.4
0.3
16.0
Having had opportunity to learn physician-industry relationships
Yes
No
107/292
185/292
36.6
63.4
Having had opportunity to learn critical appraisal skills
Yes
No
190/289
99/289
65.7
34.3
Self-reported effect of drug promotion activities on
prescribing decision
Yes
No
244/300
56/300
81.3
18.7
Self-reported effect of drug promotion activities on
Other doctors’ prescribing decision
Yes
No
270/296
26/296
91.2
8.8
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Table 2: Factors, which are rated by doctors, that affect their prescribing decisions and the
frequency of using reference sources in case of any problems in prescribing.
Factors
Level of effect
High
%
Moderate
%
Low
%
Self reading after graduation 66.4 29.5 4.1
Pharmacology courses during formal medical
education
56.1 33.1 10.7
Post-graduate in-service training 54.9 28.5 16.7
Observation of prescribing during clinical
practice in medical school
51.5 37.8 10.7
Consultation with other physicians 35.5 46.8 17.7
Activities of pharmaceutical promotion 16.6 47.8 35.6
Reference resources
Frequency
Frequently
%
Sometimes
%
Rarely
%
Medical text books 73.1 22.1 4.8
Academic journals 39.0 33.8 27.2
Consultation with Specialist/GPs 29.8 47.7 22.5
Drug guides of pharmaceutical companies 19.9 39.9 40.2
Pharmaceutical companies promotional materials
other than drug guides (brochures, posters, etc)
10.9 45.9 43.2
The extent of doctors’ exposure to pharmaceutical promotional activities
Table 3 shows respondents’ exposure to promotional activities. Most doctors met with PSRs,
received drug samples and stationery, and half of them participated in industry-sponsored
continuing medical education (CME) events at and outside the workplace. Less than half of the
respondents accepted meals outside the workplace. On average, they met with PSRs two times
per month and received gifts or participated in events nearly once per month. Internists exposed
to promotional activities most frequently (ten times per month), followed by general practitioners
(eight times per month), pediatricians (seven times per month), and obstetrician-gynecologists
(six times per month), residents (five times per month)
A total of 280 doctors (93.3% of respondents) responded to all Exposure Index items. The mean
Exposure Index was 7.46 exposures per month (SD, 7.5; range, 0-62).
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Doctors’ attitudes toward promotional activities as a factor for prescribing decision
Immunity Scores were calculated for 292 doctors who completed all items (97.3% of
respondents). The mean Immunity score was 0.67 (SD=0.29; range, 0-1.0), indicating that they
believed that they were immune from having their practice influenced by discussions with PSRs
and gifts from pharmaceutical industry.
Informational Value Scores were calculated for the 294 doctors (98%) who completed both
items. The mean Informational Value Score was 0.50 (SD, 0.26; range 0–1.0), a neutral result.
Appropriateness Scores were calculated for 293 doctors (97.6%) who completed both items. The
mean Appropriateness Score was 0.39 (SD, 0.29; range 0–1.0), indicating that they thought gifts
from PSRs were more likely to be inappropriate than to be appropriate.
Table 3: Doctors’ exposure to various types of pharmaceutical promotional activities
Type of pharmaceutical
promotion activities
Number of respondents who
meet with PSRs, receive gifts,
or participate in event
Frequency of exposure per
month
Number/Total number (%) Mean (SD)
Meetings with PSRs 280/297 (94) 2.16(2.8)
Drug samples 269/296 (91) 1.31(1.7)
Promotional materials such as
brochures, posters, etc 279/295 (95) 1.56 (1.9)
Stationery such as pens and
notepads 276/297 (93) 1.47(2.2)
Industry-sponsored CME
events 144/285 (51) 0.58(1.3)
Meals outside the workplace 85/291 (29) 0.37 (1.3)
Specialty Mean exposure per
month Number SD
Internist 9.68 46 7.9
General Practitioner 7.54 107 9.0
Pediatrics 7.32 30 4.8
Obstetrician/gynecologist 6.45 21 2.3
Residents 5.32 65 3.1
Others(Derma., Ortho., Psych) 8.64 29 10.0
Mean Exposure Index 7.46 280 7.5 (Range: 0-62)
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Doctors’ characteristics that associates with self-reported prescribing behavior
Determinants of the self-reported effect of promotional activities on prescribing decisions of
doctors have been shown in Table 4.  The percentage of the affected doctors in each of
demographic characteristics was higher than that of not affected; however the difference was not
significant.
Table 4: Adjusted odds ratios and (95% CI) association between the self-reported effect of
the promotional activities on prescribing decisions of the doctors’ and various variables (n
= 300)
Determinants Always or sometimes affected by promotional
activities OR (95% CI)
Gender
Male 1.00
Female 1.7 (0.3, 1.6)
Years of Practice
Less than 10 years 1.00
10 years and above 0.6 (0.3, 1.2)
Work Setting
Public Hospitals 1.00
Private Hospitals and Higher clinics 1.3 (0.6, 2.5)
Specialty
General Practitioner 1.00
Specialist 1.4 (0.7, 2.7)
Learning physician-pharmaceutical industry relationships
No 1.00
Yes 1.0 (0.5, 1.9)
Learning critical appraisal skills
No 1.00
Yes 0.8 (0.3, 1.6)
Differences in the extent of exposure to or attitudes toward promotional activities
according to self-reported prescribing behaviours
Table 5 shows comparison of Exposure Index according to prescribing behavior. According to
self-reported prescribing behaviors, the Exposure Index for affected doctors was significantly
greater than those whose prescribing behavior not affected (7.8/mo vs 5.7/mo; P=0.01). As
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shown on Table 6 doctors who reported affected had significantly higher mean exposure to drug
sample, promotional materials such as brochures, stationery such as pen and notepads, industry-
sponsored CME events and meals outside the workplace. The extent of exposure to promotional
activities was also greater among doctors who prefer to ask PSRs for information when a new
medication becomes available (10/mo Vs 6.8/mo; P=0.03).
The difference in the extent of exposure to promotional activities between doctors who prefer to
prescribe brand name medications when generic options are available and generic medications or
both was no statistically significant.
Table 5: Comparison of Exposure index according to prescribing behavior
Prescribing behavior Number (%)
of
respondents
Exposure Index
(range, 0-120)
Mean(SD) P-value
When a new medication
becomes available what
I do most commonly
first is
Ask PSRs for information 54/276 10.0(10.1) 0.03
Seek published literature for
effectiveness or ask
colleagues/ specialist or use on
a few patients and monitor
222/276 6.8(6.5)
When generic options
are available, I think we
should prescribe
Brand name medications 35/276 8.9(6.8) 0.16
Neutral or generic medications 241/276 7.1(7.4)
Self-reported effect of
drug promotion
activities on prescribing
decision
Yes 232/280 7.8(8.0) 0.01
No 48/280 5.7(4.2)
There was statistically significant difference in the Appropriateness Score between affected
doctors and who reported not being affected by drug promotion (0.40 Vs 0.29; range: 0-1;
P=0.01). Doctors reported affected by drug promotion perceived receiving gifts of low value as
well as high value from PSRs are appropriate (P=0.008 and P=0.05, respectively).
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There were modest but statistically significant positive correlations between Exposure Index and
Appropriateness Score (r =0.177; P=0.003). But there was no correlation between Exposure
Index and Immunity Score and between Exposure Index and Informational Value Score.
There were no differences in the Immunity Score and Informational Value Score among affected
doctors and doctors reported not being affected by drug promotion. While most doctors thought
that their own and their colleagues’ prescribing behaviors were not likely to be influenced by
gifts from PSRs, they believed that their colleagues were more likely to be influenced than
themselves (P=0.001).
Their perceptions about PSRs’ Informational Value for new medications among affected and not
affected doctors were not significantly different. The same is true for old/established
medications.
The mean Informational Value Score was significantly higher among doctors who prefer to
prescribe brand name medications when generic options are available than who prefer to
prescribe generic medications or both (0.58 Vs 0.49; range: 0-1; P=0.05). The mean difference in
Immunity Score and Appropriateness Score were not significant among doctors who prefer to
prescribe brand name medications and generic medications or neutral.
Similarly, the mean Informational Value Score was significantly higher among doctors who
prefer to ask PSRs for drug information than who prefer to seek published literature for
effectiveness or ask colleagues/ specialist or use on a few patients and monitor when a new
medication becomes available (0.60 Vs 0.48; range: 0-1, P=0.01). The mean difference in
Immunity Score and Appropriateness Score were not significant among doctors who prefer to
ask PSRs and seek information from other sources.
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Table 6: Differences in the extent of exposure to each type of promotional activities among
affected and never affected doctors according to self-reported prescribing behaviour
Promotional
Activities
Always/Sometimes affected Never Affected P-Value*
Number
(%)**
Mean
exposure per
month (SD)
Number
(%)**
Mean
exposure per
month (SD)
Meeting with PSRs 241 (80.8) 2.25(2.0) 56(19.2) 1.80 (0.8) 0.197
Promotional Materials 240(81.3) 1.66(1.2) 55(18.7) 1.16(0.7) 0.003
Stationery such as pen
and notepads 242(80.8) 1.56(1.2) 55(19.2) 1.09(0.5)
0.007
Drug samples 242(81.7) 1.381(0.8) 54(18.3) 0.99(0.6) 0.008
Industry-sponsored
CME events 236(82.8) .62(0.3) 49(17.2) 0.37(0.4)
0.20
Meals Outside the
workplace 238(81.8) 0.42(0.3) 53(18.2) 0.15(0.3)
0.15
** Row percentage
*P-value, sig (2-tailed)
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6. Discussion
Most doctors in our study reported that their prescribing decisions were always/sometimes
affected by drug promotion activities. The self-reported effect of promotion on the prescribing
decisions of doctors was significantly higher if doctors were exposed to promotional activities
frequently, i.e. more than once per week. There were differences in the extent of involvement in
different types of promotional activities. Doctors who reported that their prescribing decision
influenced by promotional activities had significantly higher mean of exposure to promotional
materials such as brochures or stationeries like pen and notepads, drug samples, industry
sponsored CME events or meals outside the work place.
Similar to our study, studies from several countries also showed that roughly 80-95% of
physicians exposed to drug promotion, resulting in inappropriate prescribing habits. It has been
reported that industry interactions correlate with doctors’ preferences for new products that hold
no demonstrated advantage over existing ones, a decrease in the prescribing of generics, and a
rise in both prescription expenditures and irrational and incautious prescribing. 17-32
Internists and general practitioners were involved in promotional activities more than the mean
Exposure index, i.e more than 7 times per month. These findings are similar to those of a
national survey in the US, which found that internists exposed to promotional activities ten times
per month more frequently than other specialists.19 These doctors may be prescribers of high
number of drugs per day. It was stated that the frequency of the visits to doctors performed by
PSRs was higher for the doctors with high number of patients per day.17
This study also provides information about doctors’ attitudes towards drug promotion activities.
There was a statistically significant difference in the Appropriateness Score between affected
doctors and who reported not being affected by drug promotion. Most affected doctors believe
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that receiving gifts from PSRs are appropriate. However, it has been reported that accepting gifts
from pharmaceutical companies allows for a potential conflict of interest between the doctor and
patient, which in some cases may be unethical. 28 The appropriateness of receiving gifts of low
value as well as high value from PSRs was high among doctors who reported affected by
pharmaceutical promotion on prescribing decisions. This finding is consistent with other surveys
that the majority of respondents considered low-value gifts as appropriate or not ethically
problematic. 31-33 Social scientists describe and the pharmaceutical industry follows the, "norm of
reciprocity" i.e., the obligation to help those who have helped you, as one of the fundamental
guiding principle of human interactions. 28, 29 It has been stated that in the context of medicine,
however, many feel that the act of accepting a gift has far reaching ethical consequences that put
the "gift" at too great a price. 62
In addition, this study shows that there were considerable but statistically significant positive
correlations between Exposure Index and Appropriateness Score. Gifts appropriateness
perception, along with the high exposure to these interactions that the doctors reported, suggests
that as they are at risk for unrecognized influence by marketing efforts.
The mean Informational Value Score was significantly higher among doctors who prefer to
prescribe brand name medications when generic medications are available. Similarly, the mean
Informational Value Score and the mean Exposure Index were significantly higher among
doctors who prefer to ask PSRs for information about new medications than who prefer to seek
published literature for effectiveness or ask colleagues/specialist or use on a few patients and
monitor when a new medications becomes available. PSRs are frequently the only source of
information about medicines in developing countries where there may be as many as one
representative for every five doctors 7. This may suggest that lack of up to date and unbiased
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sources of drug information that are accessible to doctor to learn about new medications.
Another explanation may be that PSRs provide more information about new medications for
promotional purposes.
While most doctors thought that their own and their colleagues’ prescribing behaviors were not
likely to be influenced by gifts from PSRs, they believed that their colleagues were more likely
to be influenced than themselves (P=0.01). As in other studies, doctors believed that their
colleagues were more likely to be influenced by promotional activities than themselves.28, 29
These findings are consistent with a line of social science research which shows that individuals
are susceptible to an unconscious and unintentional “self-serving bias”: judgments of fairness are
biased in favor of self-interests.30
The most common reference source used by 73.1% of the doctors in this study was medical text
books. This result is not consistent to effect of promotion on prescribing decision reported in this
study as about 81% respondents reported that they were affected by drug promotion. Similarly,
in Peru, they found that while doctors said that they relied mostly on medical literature for their
drug information, in fact their self-reported prescribing decisions were clearly not based on
this.63
Total year of practice and work setting were not found to be an influence on the pathway of
prescribing decision. In contrary to our study, it has been stated that if the general practitioners
were working at primary health care center and had an experience less than 5 years after
graduation they reported higher influence on their prescribing decision.64 Self-rated effect of
pharmaceutical promotion on prescribing decision was lower for experienced general
practitioners.17 One explanation for the inconsistent of our finding may be due to in our context,
most doctors working in public hospital may also work in private settings.
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In our survey, physician-reported educational experiences in physician-industry relationships and
critical appraisal skills did not predict the self-reported effect of drug promotion on prescribing
decision. This may be due to inaccurate self assessment of respondents’ personal levels of
educational experiences.
Generally, our findings support that promotional activities have a considerable impact on
physicians’ prescribing behaviors. Ideally, intervention studies are needed to prove whether and
to what extent promotional activities affect physicians’ prescribing behaviors.
Even though non response is one major limitation of self administered questionnaire, in our
study all the questions were almost fully answered. The participation rate was relatively high
(96%), and this was one of the strengths of our study. This might be due to the support of the
Addis Ababa RHB and perseverance of the data collector.
This survey has some limitations. First, the fact that this study was based on self-report of
doctors about the effect of pharmaceutical promotion on their prescribing decision the reliance of
self-report is one of the main issues of the studies similar to ours. Second, the cross-sectional
nature of the survey does not allow us to infer causality of the associations.
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7. Conclusion
This paper suggests that promotional activities have considerable impact on physicians’
prescribing behaviors. Doctors’ involvement in and/or attitudes toward drug promotion were
found to be the main factors that affect doctors prescribing decision rather than their socio-
demographic characteristics. According to self-reported effect on prescribing behavior, doctors
who perceived that gifts from drug companies are appropriate and PSRs as valuable source of
drug information were highly affected by drug promotion. The extent of exposure was higher
among doctors who prefer to ask PSRs for information when a new medication becomes
available and doctors who prefer to prescribe brand-name medications. Taken together, all these
results indicate a lack of formal drug information sources and an adequate control of promotional
activities by government bodies or professional societies.
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8. Recommendations
We recommend that:
 Government bodies and/or professional societies should provide drug information
services to doctors so that they will have access to unbiased drug information.
 Hospitals’ Drug and Therapeutic Committees (DTCs) should design effective
intervention strategies to overcome the possible impact of pharmaceutical promotion in
their health facility drug use practice.
 FMHACA should update and effectively implement the drug promotion guideline giving
due emphasis on promotional gifts.
 Professional societies should promulgate code of ethics concretely defining appropriate
interactions between physicians and pharmaceutical industry or prohibiting inappropriate
interactions.
Findings of this study suggest but do not prove that promotional activities have a considerable
impact on physicians’ prescribing behaviors. Further research may be required to understand
exactly how much influence and to what degree promotional activities affect physicians’
prescribing behaviors.
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Annex I. Consent Form
Study Title: Assessment on the impact of pharmaceutical promotion on prescribing decisions of
doctors in hospitals and higher clinics of Addis Ababa.
Dear Doctor,
My name is Mengistu Tadesse and working for Pfizer Inc. I am final year student of Addis
Continental Institute of Public Health and University of Gondar Joint MPH program here in
Addis Ababa. My telephone number is 0911668723. We are conducting a study on assessment
on the impact of pharmaceutical promotion on prescribing decisions of doctors in hospitals and
higher clinics of Addis Ababa. The information collected will help to improve the rational use of
drugs here in Addis.
You will be asked to fill out a self administered questionnaire about your demographic and your
prescribing decision in relation to promotional activities. Your name will not appear on this
questionnaire and all the information you provide will be strictly confidential. You are not
obliged to answer any questions that you don’t wish to answer, and you can put an end to this
interview at any time, if you wish to do so. Your participation in this study does not involve any
direct risk or benefit for you but it is very useful since your answers, as well as those of other
participants, will help to improve the problem related to drug use. Would you like to participate
in the study?
Yes___________    No____________
Signature: ___________________________________________
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Annex II: Self-Administered Questionnaire
Assessment on the impact of pharmaceutical promotion on prescribing decisions of doctors
in hospitals and higher clinics of Addis Ababa
I. Demographic Characteristics: Please provide your background information under the
following headings
1. Gender
Male Female
2. Years of practice
1–3 4–6 7–9 10 and above
3. Work Setting
Private Hospital Public Hospital Higher Clinic
4. Specialty
Internal Medicine Dermatology
Surgery Psychiatry
Orthopedics Ophthalmology
Pediatrics General Practitioner
Obstetrics/gynecology Other  [ ]
Resident [                                           ]
5. University you are graduated in          Under Post
Addis Ababa University graduate
Gondar University graduate
Jimma University graduate
Debub University graduate
Other  [ ]
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II. Survey questions about prescribing decision and its determinants
6. Please rate the factors below according to the level of the effect on your prescribing
decision in the order of 1 (low) to 6 (high).
7. Please rate the references that you consulted according to frequency of use in case of
any problem in prescribing, in the order of 1 (rarely) to 6 (frequently).
8. Which of the followings do you do first most commonly when a new medication
becomes available?
Seek published findings for its effectiveness
Ask colleagues/specialists for their opinions
Collect information from pharmaceutical sales representatives
Use on a few patients and monitor
9. Do the activities of drug promotion affect your prescribing decision?
Yes/always Yes/sometimes No
10. Do you think the activities of drug promotion of drug companies affect other doctors’
prescribing decision?
Yes/always Yes/sometimes No
Factors Low                                  High
1 2 3 4 5 6
Pharmacology courses during formal medical
education.
Activities of Pharmaceutical Promotion
Observation of prescribing during clinical practice in
medical school
Post-graduate in-service training
Consultations with other physicians
Self-reading after graduation
References Rarely Frequently
1 2 3 4 5 6
Drug guides of pharmaceutical companies
Pharmaceutical companies promotional materials
other than drug guides (brochures, posters, etc...)
Medical text books
Academic journals
Consultation with a specialist doctor/GP
42
III. Survey questions about doctors involvement in promotional activities
11. On average, how often do you meet Pharmaceutical Sales Representatives (PSRs)?
Never Less than
once a
month
once a
month
Twice or
three
times a
month
Once a
week
Twice or
three times
a week
Nearly
everyday
12. On average, how often do you receive or participate in the following gifts or
promotional materials or events?
Gifts/promotional
materials/Events
Never Less
than
once a
month
Once a
month
Twice or
three
times a
month
Once a
week
Twice or
three
times a
week
Nearly
everyday
Drug samples
Promotional Materials
such as brochures,
posters, etc
Stationery such as pens
and notepads
Industry-sponsored
CME events
Meals outside the
workplace
Financial subsidies to
attend CME events
/international
conferences
Never Less than once a year Once a year More than once a
year
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IV. Survey questions about impact of drug promotion activities on prescribing behaviors
13. To what extent do you agree/disagree the following statements regarding impact of
drug promotion activities on your prescribing behaviors?
a. Discussions with Pharmaceutical Sales Representatives (PSRs) have an unfavorable impact
on my prescribing behaviors.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
b. Gifts/promotional materials from Pharmaceutical Sales Representatives (PSRs) have an
unfavorable impact on my prescribing behaviors, regardless of the monetary value
Gifts/promotional
materials
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
Drug samples
Promotional Materials such
as brochures, posters, drug
guides, etc
Stationery such as pens,
notepads, chips, etc
Other gifts such us watches,
stethoscope, any medical
equipments etc.
c. Meals or entertainments from Pharmaceutical Sales Representatives (PSRs) have an
unfavorable impact on my prescribing behaviors.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
d. Pharmaceutical Industry-sponsored CME events have an unfavorable impact on my
prescribing behaviors.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
e. Financial subsidies to attend international conferences/CME events have an unfavorable
impact on my prescribing behaviors.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
f. Gifts from Pharmaceutical Sales Representatives (PSRs) have an unfavorable impact on
other physicians’ prescribing behaviors, regardless of the monetary value
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
g. It is appropriate to receive gifts of low monetary value from Pharmaceutical Sales
Representatives (PSRs)
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
h. It is appropriate to receive gifts of high monetary value from Pharmaceutical Sales
Representatives (PSRs).
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Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
i. Pharmaceutical Sales Representatives (PSRs) provide accurate information about new
medications.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
j. Pharmaceutical Sales Representatives (PSRs) provide accurate information about old
(established) medications.
Agree Somewhat
agree
Neutral Somewhat
disagree
Disagree
14. When generic options are available, which of generic or brand-name medications do
you think you should prescribe?
Prescribe generic medications
Neutral
Prescribe brand-name medications
15. To what extent have you had an opportunity to learn physician-pharmaceutical
industry relationships?
None Little A little Some Substantial
16. To what extent have you had an opportunity to learn critical appraisal skills of the
medical literature about treatment?
None Little A little Some Substantial
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